Influenza tetravalent vaccines in national immunization programs for Latin-American countries
Creators
- Macías Hernández, Alejandro E.
- Santos, Fortino Solórzano
- Aguilar Velasco, Hugo M.
- Ávila Agüero, María L.
- Rubio, Fernando Bazzino
- Junqueira Bellei, Nancy C.
- Bonvehí, Pablo E.
- Del Castillo, José Brea
- Leguizamón, Héctor Castro
- Allan Santos Domingues, Carla M.
- García García, María D.L.
- Trujillo, Darío Londoño
- Lópe, Pío López
- De León Rosales, Samuel Ponce
- Cervantes Powell, Patricia G.
- Suárez Ognio, Luis A.N.
- Ruiz-Palacios y Santos, Guillermo M.
Description
Since 2012-2013 influenza season, World Health Organization (who) recommends the formulation of tetravalent vaccines. Globally, many countries already use tetravalent vaccines in their national immunization programs, while in Latin America only a small number. Two Influenza b lineages co-circulate, their epidemiological behavior is unpredictable. On average they represent 22.6% of influenza cases and more than 50% in predominant seasons. The lack of concordance between recommended and circulating strains was 25 and 32% in the 2010-2017 and 2000-2013 seasons, respectively. There are no clinical differences between influenza A and B. It occurs more frequently from five to 19 years of age. Influenza b has a higher proportion of attributable deaths than influenza a (1.1 vs. 0.4%), or 2.65 (95% ci 1.18-5.94). A greater number of hospitalizations when the strains mismatch (46.3 vs. 28.5%; p <.0001). Different evaluations have demonstrated its cost effectiveness. The compilation of this information supports the use of quadrivalent vaccines in Latin American countries.
Files
Vacunatetravalente.pdf
Files
(247.0 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:275ab9e4aab9f91375e79f9cd45660cd
|
247.0 kB | Preview Download |
Additional details
Related works
- Is published in
- https://repositorioacademico.upc.edu.pe/handle/10757/655697 (URL)